36 results
6-K
EX-99.1
SCNI
Scinai Immunotherapeutics Ltd
25 Apr 24
Report of Foreign Private Issuer
4:00pm
patients may suffer from considerable and visible lesions which may be uncomfortable, painful, and impact social and men tal well - being Mild patients
6-K
EX-99.1
SCNI
Scinai Immunotherapeutics Ltd
16 Apr 24
Report of Foreign Private Issuer
5:27pm
, painful, and impact social and mental well - being Mild patients are ineligible for biological treatments in most cases; and moderate psoriatic
6-K
EX-99.1
SCNI
Scinai Immunotherapeutics Ltd
18 Jan 24
Report of Foreign Private Issuer
11:50am
considerable and visible lesions which may be uncomfortable, painful, and impact social and men tal well - being Mild patients are ineligible for biological
6-K
EX-99.1
SCNI
Scinai Immunotherapeutics Ltd
9 Jan 24
Report of Foreign Private Issuer
8:45am
and visible lesions which may be uncomfortable, painful, and impact social and men tal well - being Mild patients are ineligible for biological treatments
6-K
EX-99.1
SCNI
Scinai Immunotherapeutics Ltd
5 Jul 23
Report of Foreign Private Issuer
9:28am
heart rate and social behaviors. Milder illness and faster recovery of hamsters infected with SARS - COV - 2 then treated with inhaled anti - COVID - 19
8-K
EX-99.1
qqir yutiedxvzrcy1
4 May 23
Regulation FD Disclosure
9:25am
10-K
n9n 6qnbawuv4
17 Apr 23
Annual report
4:06pm
6-K
EX-99.1
oprjxfcwcxosa1i8fxk2
29 Dec 22
Report of Foreign Private Issuer
10:39am
424B4
zb6pzaa l3srkd2a1
20 Dec 22
Prospectus supplement with pricing info
11:59am
F-1/A
0tiol58mvr8fj brtlql
12 Dec 22
Registration statement (foreign) (amended)
5:25pm
6-K
EX-99.1
e9dkmhf4ndc7d0dc
29 Nov 22
BiondVax reports successful results in preclinical in vivo study of its innovative inhaled COVID-19 NanoAb therapy
11:09am
F-1
4xavamy6p7 c7seari
29 Sep 22
Registration statement (foreign)
9:22am
6-K
EX-1.1
kk5cdf
2 Oct 20
BiondVax Announces At-The-Market (ATM) Equity Offering Program
12:00am
6-K
EX-99.1
dkl54ypw7ra
1 Sep 20
Report of Foreign Private Issuer
7:18am